Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CAMKK1 | Q8N5S9 | 2/20 | 0.34 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.34 |
| ▸ | NEK2 | P51955 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2832540 | 0.87 | LMNA (0.38) | LMNAHPGDPTGDR2KMT2AMEN1 | |
| SCHEMBL2830912 | 0.72 | KEAP1 (0.40) | LMNANEK2 | |
| SCHEMBL19259924 | 0.70 | CYP1A2 (0.37) | HPGDALDH1A1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL19259801 | 0.70 | CD38 (0.41) | KMT2AMEN1ALDH1A1POLBNPC1 | |
| SCHEMBL27771263 | 0.69 | ABCC1 (0.42) | LMNAPTGDR2KMT2ACAMKK1CAMKK2 | |
| SCHEMBL8167370 | 0.68 | LMNA (0.42) | LMNAPTGDR2KMT2AMEN1CAMKK1 | |
| SCHEMBL27792331 | 0.67 | GPR35 (0.41) | LMNAHPGDCAMKK1CAMKK2ALDH1A1 | |
| SCHEMBL10369652 | 0.67 | LMNA (0.30) | LMNA | |
| Ammonia Solution, Strong SCHEMBL27837724 | 0.66 | — | — | |
| SCHEMBL28854812 | 0.65 | MAPK10 (0.43) | LMNAPTGDR2KMT2AMEN1CAMKK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054480-A1 | NOVEL QUINUCLIDINE CARBAMATE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | LABORATORIOS ALMIRALL S.A. | 2009-02-26 | — | — | US | disclosed |
| US-20090005412-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | LABORATORIOS ALMIRALL S.A. | 2009-01-01 | — | — | US | disclosed |
| US-7435742-B2 | Quinuclidine derivatives and pharmaceutical compositions containing the same | LABORATORIOS ALMIRALL S.A. (ES) | 2008-10-14 | — | — | US | disclosed |
| US-20060094751-A1 | Quinuclidine derivatives and pharmaceutical compositions containing the same | ALMIRALL, S.A. (ES) | 2006-05-04 | — | — | US | disclosed |
| EP-1515968-A2 | QUINUCLIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Almirall Prodesfarma AG (CH) | 2005-03-23 | — | — | EP | disclosed |
| WO-2004000840-A2 | QUINUCLIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL PRODESFARMA AG (CH) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005412-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | CHRM3, CHRM2, CHRM1 | LMNA 4384/4885HPGD 2312/4885PTGDR2 1173/4885 |
| US-20060094751-A1 | Quinuclidine derivatives and pharmaceutical compositions containing the same | CHRM3, CHRM2, CHRM1 | LMNA 4134/4885HPGD 2118/4885PTGDR2 1100/4885 |
| US-20090054480-A1 | NOVEL QUINUCLIDINE CARBAMATE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | CHRM3, CHRM2, CHRM1 | LMNA 4450/4885HPGD 2262/4885PTGDR2 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.